Ticker

One IPO and six SPACs came to market this past week, and one major issuer joined the pipeline as February comes to a close. One large IPO is currently scheduled in the week ahead, although some smaller issuers may join the calendar throughout the week. Street research is expected for seven companies in the week ahead, and one lock-up period will be expiring.

Flagship-backed Generate Biomedicines' shares fell 6.25% in its Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious toward new listings.

Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares at $16 each.

SOMERVILLE, Mass., Feb. 26, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16.00 per share.

Drug developer Generate Biomedicines said on Monday it was aiming to raise as much as $425 million in its initial public offering in the United States.